Pharmaceutical Technology

SEPTEMBER 30, 2022

Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. Prior to bluebird's approvals, there were only two FDA-approved gene therapies for inherited conditions on the market.

FDA 115

FDA Insurance Patients Marketing 115

pharmaphorum

JULY 25, 2022

The new drug is one of two bispecifics for multiple myeloma in the late-stage pipeline of J&J’s Janssen division stemming from its longstanding and fertile collaboration with Danish biotech Genmab, along with talquetamab which binds to CD3 and GPRC5D.

Medicine 52

Medicine FDA Recruitment Patients 52

Pharmaceutical Technology

APRIL 13, 2023

Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. While stem cell transplants can cure the condition, their use is limited due to some of the risks that come with them.

Healthcare 59

Healthcare Healthcare Pharmaceutical FDA 59

Clarify Health

NOVEMBER 22, 2023

This increase can be attributed to many things, including an aging population, the increasing prevalence of chronic conditions, and greater access to care stemming from expanded insurance coverage. With higher price tags, the incentive for quality improvement is lower, setting back efforts to drive value-based care.

Leads 52

Leads Healthcare Healthcare Patients 52

CloserIQ

NOVEMBER 9, 2018

” The Ultimate Guide to Gifting STEM toys: Tons of Ideas for Little builders (TechCrunch). “There are a few devices in the market that are essentially fully fledged computers — but with a child-friendly layer applied to hand-hold and gamify STEM learning.” ” What happens to employees after an acquisition?

Recruitment 49

Recruitment Sales Management Sales Prospecting 49

pharmaphorum

AUGUST 18, 2022

Zynteglo is a customised, one-time treatment created using a patient’s own bone marrow stem cells hat are genetically modified to produce functional beta-globin, which is mutated in the disease. million price tag attached to the therapy when it was first made available in Europe, and is also well above the proposed $2.1

FDA 52

FDA Insurance Patients Medical 52

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. Currently, all approved CAR-T therapies are autologous, where T cells taken from patients are modified and then re-infused.

Food and Drug Administration 59

Food and Drug Administration Engineering Patients Education 59